Clinical Trial Update: Long-term Ambrisentan Extension Study for Pediatric Patients Who Participated in AMB112529 [Phase 2]

View source ↗

Summary

Phase 2 pediatric long-term extension study of ambrisentan for hypertension/pulmonary hypertension completed; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertension
• Pulmonary Arterial Hypertension

Drugs mentioned

• Ambrisentan (Ambrisentan)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Hypertension, Pulmonary | Phase 2 | Status: COMPLETED | Results posted: 2022-12-30